Dominic O'Connor1, Malcolm Brown2, Martin Eatock3,4, Richard C Turkington3,4, Gillian Prue2. 1. School of Nursing and Midwifery, Queen's University, 8 Fitzwilliam Street, Belfast, Northern Ireland, BT9 6AW, UK. dominic.oconnor@qub.ac.uk. 2. School of Nursing and Midwifery, Queen's University, 8 Fitzwilliam Street, Belfast, Northern Ireland, BT9 6AW, UK. 3. The Northern Ireland Cancer Centre, Belfast City Hospital, Belfast, Northern Ireland. 4. The Patrick G Johnston Centre for Cancer Research, Queen's University, Belfast, Northern Ireland.
Abstract
BACKGROUND: Surgical resection remains the only curative treatment for pancreatic cancer and is associated with significant post-operative morbidity and mortality. Patients eligible for surgery, increasingly receive neo-adjuvant therapy before surgery or adjuvant therapy afterward, inherently exposing them to toxicity. As such, optimizing physical function through exercise during treatment remains imperative to optimize quality of life either before surgery or during rehabilitation. However, current exercise efficacy and prescription in pancreatic cancer is unknown. Therefore, this study aims to summarise the published literature on exercise studies conducted in patients with pancreatic cancer undergoing treatment with a focus on determining the current prescription and progression patterns being used in this population. METHODS: A systematic review of four databases identified studies evaluating the effects of exercise on aerobic fitness, muscle strength, physical function, body composition, fatigue and quality of life in participants with pancreatic cancer undergoing treatment, published up to 24 July 2020. Two reviewers independently reviewed and appraised the methodological quality of each study. RESULTS: Twelve studies with a total of 300 participants were included. Heterogeneity of the literature prevented meta-analysis. Exercise was associated with improvements in outcomes; however, study quality was variable with the majority of studies receiving a weak rating. CONCLUSIONS: High quality evidence regarding the efficacy and prescription of exercise in pancreatic cancer is lacking. Well-designed trials, which have received feedback and input from key stakeholders prior to implementation, are required to examine the impact of exercise in pancreatic cancer on key cancer related health outcomes.
BACKGROUND: Surgical resection remains the only curative treatment for pancreatic cancer and is associated with significant post-operative morbidity and mortality. Patients eligible for surgery, increasingly receive neo-adjuvant therapy before surgery or adjuvant therapy afterward, inherently exposing them to toxicity. As such, optimizing physical function through exercise during treatment remains imperative to optimize quality of life either before surgery or during rehabilitation. However, current exercise efficacy and prescription in pancreatic cancer is unknown. Therefore, this study aims to summarise the published literature on exercise studies conducted in patients with pancreatic cancer undergoing treatment with a focus on determining the current prescription and progression patterns being used in this population. METHODS: A systematic review of four databases identified studies evaluating the effects of exercise on aerobic fitness, muscle strength, physical function, body composition, fatigue and quality of life in participants with pancreatic cancer undergoing treatment, published up to 24 July 2020. Two reviewers independently reviewed and appraised the methodological quality of each study. RESULTS: Twelve studies with a total of 300 participants were included. Heterogeneity of the literature prevented meta-analysis. Exercise was associated with improvements in outcomes; however, study quality was variable with the majority of studies receiving a weak rating. CONCLUSIONS: High quality evidence regarding the efficacy and prescription of exercise in pancreatic cancer is lacking. Well-designed trials, which have received feedback and input from key stakeholders prior to implementation, are required to examine the impact of exercise in pancreatic cancer on key cancer related health outcomes.
Authors: M Ducreux; A Sa Cuhna; C Caramella; A Hollebecque; P Burtin; D Goéré; T Seufferlein; K Haustermans; J L Van Laethem; T Conroy; D Arnold Journal: Ann Oncol Date: 2015-09 Impact factor: 32.976
Authors: N Pecorelli; G Carrara; F De Cobelli; G Cristel; A Damascelli; G Balzano; L Beretta; M Braga Journal: Br J Surg Date: 2016-01-18 Impact factor: 6.939
Authors: John P Neoptolemos; Daniel H Palmer; Paula Ghaneh; Eftychia E Psarelli; Juan W Valle; Christopher M Halloran; Olusola Faluyi; Derek A O'Reilly; David Cunningham; Jonathan Wadsley; Suzanne Darby; Tim Meyer; Roopinder Gillmore; Alan Anthoney; Pehr Lind; Bengt Glimelius; Stephen Falk; Jakob R Izbicki; Gary William Middleton; Sebastian Cummins; Paul J Ross; Harpreet Wasan; Alec McDonald; Tom Crosby; Yuk Ting Ma; Kinnari Patel; David Sherriff; Rubin Soomal; David Borg; Sharmila Sothi; Pascal Hammel; Thilo Hackert; Richard Jackson; Markus W Büchler Journal: Lancet Date: 2017-01-25 Impact factor: 79.321
Authors: Theresa P Yeo; Sherry A Burrell; Patricia K Sauter; Eugene P Kennedy; Harish Lavu; Benjamin E Leiby; Charles J Yeo Journal: J Am Coll Surg Date: 2012-02-07 Impact factor: 6.113
Authors: Kerry S Courneya; Donald C McKenzie; Robert D Reid; John R Mackey; Karen Gelmon; Christine M Friedenreich; Aliya B Ladha; Caroline Proulx; Kirstin Lane; Jeffrey K Vallance; Roanne J Segal Journal: Ann Behav Med Date: 2008-02-20
Authors: Keri L Schadler; Nicholas J Thomas; Peter A Galie; Dong Ha Bhang; Kerry C Roby; Prince Addai; Jacob E Till; Kathleen Sturgeon; Alexander Zaslavsky; Christopher S Chen; Sandra Ryeom Journal: Oncotarget Date: 2016-10-04
Authors: Tora S Solheim; Barry J A Laird; Trude Rakel Balstad; Guro B Stene; Asta Bye; Neil Johns; Caroline H Pettersen; Marie Fallon; Peter Fayers; Kenneth Fearon; Stein Kaasa Journal: J Cachexia Sarcopenia Muscle Date: 2017-06-14 Impact factor: 12.910
Authors: Claudia Alvarez Florez Bedoya; Ana Carolina Ferreira Cardoso; Nathan Parker; An Ngo-Huang; Maria Q Petzel; Michael P Kim; David Fogelman; Salvador Gabriel Romero; Huamin Wang; Minjeong Park; Matthew H G Katz; Keri L Schadler Journal: Sci Rep Date: 2019-09-27 Impact factor: 4.379
Authors: An Ngo-Huang; Nathan H Parker; Eduardo Bruera; Rebecca E Lee; Richard Simpson; Daniel P O'Connor; Maria Q B Petzel; Rhodora C Fontillas; Keri Schadler; Lianchun Xiao; Xuemei Wang; David Fogelman; Sunil K Sahai; Jeffrey E Lee; Karen Basen-Engquist; Matthew H G Katz Journal: Integr Cancer Ther Date: 2019 Jan-Dec Impact factor: 3.279